Natera, Inc. (NTRA) is in Healthcare, Diagnostics & Research, based in United States, listed on NasdaqGS. Market cap 58.02B USD. 52-week range 167.99 to 437.41 USD. Data as of 2026-10-09.
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also ...